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Across vertebrates, there are three principal skeletal tissues: bone, persistent cartilage, and replacement cartilage. Although each tissue
has a different evolutionary history and functional morphology, they also share many features. For example, they function as structural
supports, they are comprised of cells embedded in collagen-rich extracellular matrix, and they derive from a common embryonic stem
cell, the osteochondroprogenitor. Occasionally, homologous skeletal elements can change tissue type through phylogeny. Together, these
observations raise the possibility that skeletal tissue identity is determined by a shared set of genes. Here, we show that misexpression of
either Sox9 or Runx2 can substitute bone with replacement cartilage or can convert persistent cartilage into replacement cartilage and
vice versa. Our data also suggest that these transcription factors function in a molecular hierarchy in which chondrogenic factors
dominate. We propose a binary molecular code that determines whether skeletal tissues form as bone, persistent cartilage, or replacement
cartilage. Finally, these data provide insights into the roles that master regulatory genes play during evolutionary change of the vertebrate
skeleton.
D 2004 Elsevier Inc. All rights reserved.
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evolutionIntroduction
Early vertebrates evolved a variety of skeletal tissues in
response to different selective pressures (deBeer, 1937;
Huxley, 1858; Maisey, 1988; Smith and Hall, 1990). Bone
arose as a rigid and protective external armor, while two types
of cartilage developed to provide flexible, internal support for
such structures as gills and sensory organs. The two cartilages
differ in that one persists throughout an organism’s life,
whereas the other serves as a template that is replaced by bone
during endochondral ossification. Both persistent cartilage
and replacement cartilage express Collagen type IIa1 (Col2)0012-1606/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.ydbio.2004.07.006
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replacement cartilage undergo hypertrophy and express
Collagen type Xa1 (Col10). Bone expresses Collagen type
Ia2 (Col1) and stains with Alizarin red.
Master regulatory genes for skeletal histogenesis or tissue
formation have been identified, but the manner by which they
specify distinct tissue types is unclear. The Sry-related
transcription factor Sox9 activates the expression of genes
associated with the cartilage phenotype, such as Col2 and
Aggrecan (Lefebvre et al., 1997; Sekiya et al., 2000). Sox9 is
required for the differentiation of both persistent and
replacement cartilages (Akiyama et al., 2002; Yan et al.,
2002). Also, Sox9 is sufficient for cartilage formation, since
Sox9 misexpression produced ectopic cartilage (Bell et al.,
1997; Healy et al., 1999; Kanzler et al., 1998). Whether these
ectopic nodules demonstrated markers of persistent or
replacement cartilage was not addressed.274 (2004) 188–200
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PEBP2aA/Osf2/AML3) was identified initially as a
positive regulator of genes associated with the bone
phenotype, such as Collagen type Ia2 and Osteocalcin
(Ducy et al., 1997). Indeed, Runx2 is required for bone
formation (Komori et al., 1997; Otto et al., 1997). The
sufficiency of Runx2 in driving bone formation was
suggested by the fact that Runx2 could induce the ectopic
expression of bone markers in nonosteoblast tissue culture
lines (Ducy et al., 1997), but this finding lacks in vivo
support. Widespread Runx2 expression in limb mesen-
chyme did not produce ectopic bone (Stricker et al., 2002).
Indicative of the overlapping nature of molecular controls
for skeletogenesis, Runx2, a transcription factor required
for the differentiation of bone, also participates in replace-
ment cartilage formation. Runx2 is required for replace-
ment cartilage formation (Hoshi et al., 1999; Inada et al.,
1999; Kim et al., 1999). Transgenic expression from a
Col2 promoter demonstrated that Runx2 is sufficient to
transform a persistent cartilage to replacement cartilage,
which in turn induced ectopic endochondral bone (Takeda
et al., 2001; Ueta et al., 2001). However, the sufficiency of
Runx2 for inducing intramembranous ossification in vivo
remains hypothetical.
Although such studies suggest that replacement cartilage,
bone, and persistent cartilage might arise through the
overlapping actions of Sox9 and Runx2, the rules governing
this synergy are unknown. To elucidate the roles of
molecular determinants in dictating skeletal histogenesis,
we analyzed Sox9 and Runx2 functions in the cranial
skeleton, where the development of replacement cartilage,
bone, and persistent cartilage is spatially distinct. Differ-
ential expression of Sox9 and Runx2 correlated with three
skeletal fates as cranial neural crest cells initiated histo-
genesis. We confirmed Sox9 and Runx2 as functional
regulators of cranial skeletogenesis by viral misexpression.
Sox9 misexpression produced ectopic cartilage, while
Runx2 misexpression resulted in ectopic bone. Closer
histological and molecular analyses of Sox9- or Runx2-
treated embryos revealed transformations of skeletal tissue
fate, the most striking of which was the appearance of
replacement cartilage within bone as a result of Sox9
misexpression. We further supported this conclusion by
comparing our experimental phenomenon with secondary
cartilage, a tissue in normal, uninfected embryos, which
results from a conversion of cells from osteogenic to
chondrogenic fates (Buxton et al., 2003; Hall, 1986). In
addition, Sox9 misexpression transformed replacement
cartilage to persistent cartilage, whereas ectopic Runx2
expression converted persistent cartilage to replacement
cartilage. From both the restricted pattern of these skeletal
tissue transformations and expression data in uninfected
embryos, we propose that chondrogenic determinants are
dominant to osteogenic ones in skeletogenic cell fate
decisions. In closing, our findings have direct implications
for analyzing evolutionary phenomena in molecular terms.Materials and methods
Embryo collection
Chick (Gallus gallus) embryos were staged (Hamburger
and Hamilton, 1951) and fixed in 4% paraformaldehyde
overnight at 48C. All reagents, unless otherwise stated, are
from Sigma Chemicals (St. Louis, MO).
Histology
Embryos were dehydrated through an ethanol series. To
detect bone and cartilage, whole-mount embryos were
stained with Alcian blue and Alizarin red and cleared in
glycerol as described (Wassersug, 1976). Paraffin-embed-
ded sections underwent Safranin O (Ferguson et al., 1998)
and Hall-Brunt-Quadruple (HBQ; Hall, 1986) histological
protocols. In HBQ, Alcian blue stains cartilage matrix and
direct red stains bone matrix. Images were captured in
Adobe Photoshop.
Cartilage and bone matrix quantitation
Sections used were limited to those containing the
lower beak and hyoid skeleton, outlined by the spe-
cific anatomical landmarks in Supplementary Fig. 1.
Adobe Photoshop was used to quantify bone and car-
tilage matrix in JPEG files of HBQ-stained sections.
Pixel counts were totaled for each sample, and statistical
significance between samples was determined by Student
t test.
RNA in situ hybridization
Radioactive antisense probe production and RNA in
situ hybridization were performed on tissue sections as
described (Albrecht et al., 1997). vEnv probe was a gift
from C. Tabin; all others were reported in previous
publications. The Runx2 and Sox9 probes recognize
both endogenous and viral transcripts. Images were
captured in Adobe Photoshop, and silver grains were
pseudocolored.
RCAS proviral constructs
RCAS–Sox9, which contains full-length chick Sox9,
was described previously (Healy et al., 1999). RCAS–
Runx2, which contains full-length chick Runx2, was
described previously (Stricker et al., 2002). RCAS–AP
was described previously (Fekete and Cepko, 1993); it
contains a full-length bacterial alkaline phosphatase that
is resistant to a heat treatment that normally kills the
activity of endogenous vertebrate alkaline phosphatases,
allowing virally infected cells to be distinguished from
normal skeletogenic, alkaline phosphatase-expressing
cells.
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RCAS virus was produced as described (Morgan and
Fekete, 1996); DF-1 cells were from C. Tabin or American
Type Culture Collection (Manassus, VA). One microliter of
0.02% fast green FCF was added to 10 Al of viral supernatant
(N109 IU/ml) for visualization. Virus was drawn into a pulled
borosilicate glass capillary needle (O.D.: 1.0 mm; I.D.: 0.50
mm; Sutter Instrument Co., Novato, CA) attached to a KITE-
R micromanipulator (World Precision Instruments, Sarasota,
FL) and injected into the lumen of the neural tube at the
midbrain/hindbrain junction of HH8-10 embryos using a
PV830 Pneumatic Picopump (World Precision Instruments).Fig. 1. Binary molecular code for three skeletal cell fates. Coronal sections of unin
HH26 mandible (A, D, G, J), ceratobranchial in HH26 hyoid (B, E, H, K), and sur
demonstrates mesenchymal condensation (outline). (D–L) RNA in situ hybridizati
cell fates. Sox9 and Col2 transcripts are high in persistent and replacement carti
persistent cartilage (J) but is high in replacement cartilage and bone (K, L). Note(*
cartilage (C, F, I, L), two persistent cartilages, conform to the molecular code. Abbr
Scale bars: 100 Am (A, B, D, E, G, H, J, K); 250 Am (C, F, I, L).Results
Differential expression of Sox9 and Runx2 in skeletogenic
condensations
If Sox9 and Runx2 are functional regulators of
skeletogenic cell fate decisions, then they should be
expressed during mesenchymal condensation, as cells
initiate skeletogenesis. We analyzed Sox9 and Runx2
expression in the chick cranial skeleton, where mesenchy-
mal condensations of replacement cartilage, bone, and
persistent cartilage are spatially distinct. Before overt
skeletogenesis, both Sox9 and Runx2 were expressed infected embryos through cells initiating histogenesis of Meckel’s cartilage in
angular in HH29 mandible (C, F, I, L). (A–C) Safranin O/fast green staining
on reveals unique Sox9 and Runx2 expression patterns among three skeletal
lages (D, E, G, H) but are low in bone (F, I). Runx2 expression is low in
) that the expression profiles of the basibranchial (B, E, H, K) and Meckel’s
eviations: b indicates bone; pc, persistent cartilage; rc, replacement cartilage.
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in cranial neural crest cells by Hamburger Hamilton stage
15 (HH15) and later were down-regulated in cells that
were not undergoing chondrogenesis (data not shown). As
persistent and replacement cartilages initiated histogenesis
at HH26, they both expressed Sox9 and Col2; nonetheless,
their ultimate cell fate could be easily distinguished,
because only replacement cartilage expressed Runx2 (Figs.
1A, B, D, E, G, H, J, K). Runx2 transcripts were not
apparent in craniofacial mesenchyme before HH24 (data not
shown). As bone initiated histogenesis at HH29, transcripts
for Runx2 were abundant, and Sox9 and Col2 transcripts
were undetectable (Figs. 1C, F, I, L). We summarized these
expression data into a binary molecular code, which we
hypothesized would specify all three skeletal tissue fates
(Fig. 1).
Sox9 and Runx2 drive cranial skeletogenesis
To test the functional significance of this code, we
misexpressed Sox9 or Runx2 using a viral gain of
function approach. Injection of virus into neural tubes
of HH8-10 (Hamburger and Hamilton, 1951) chick
embryos resulted in widespread infection of the majorityFig. 2. Sox9 and Runx2 misexpression affect skeletal cell fate decisions. Alizari
HH36 embryos. Compared to mandibles of AP-treated embryos (A), mandibles of
treated embryos show ectopic bone (C). The location of ectopic bone at a distance f
hyoid skeleton, normally composed of the epibranchial, a persistent cartilage (pc),
embryos (D). (E) Sox9 misexpression inhibits ceratobranchial mineralization, sug
causes ectopic epibranchial mineralization, suggesting transformation to replac
replacement cartilage. Scale bars: 0.2 cm (A–C); 0.1 cm (D–F).of craniofacial mesenchyme. Compared to control
embryos infected with a virus encoding alkaline phos-
phatase (AP-treated), Sox9-treated embryos developed
ectopic cartilage nodules throughout the head (72/76;
Fig. 2A, B, see also Fig. 4B). No ectopic bone resulted
from ectopic Sox9 expression. These data are in agree-
ment with results from Sox9 misexpression in limb
mesenchyme (Healy et al., 1999). Our Runx2 misexpres-
sion experiments, however, are in contrast to those
performed on the limb (Stricker et al., 2002). We found
that Runx2-treated embryos developed ectopic bone (21/
26; Figs. 2A, C). Despite the role of Runx2 in replace-
ment cartilage development (Inada et al., 1999; Ueta et
al., 2001), no ectopic cartilage resulted from Runx2
misexpression. The gross appearances of ectopic cartilage
in Sox9-treated embryos and ectopic bone in Runx2-
treated embryos illustrated the functional roles of these
transcription factors in cranial skeletogenesis.
Despite the widespread expression of Sox9 and
Runx2 in virally infected embryos, all skeletal elements
still formed in their proper anatomical locations,
although occasionally their shapes were altered. Thus,
skeletal morphogenesis appeared largely unaffected. Sox9
and Runx2 misexpression did, however, transform then red/Alcian blue-stained mandibular (A–C) and hyoid (D–F) skeletons of
Sox9-treated embryos have ectopic cartilage (B), and mandibles of Runx2-
rom cartilage in C reflects ectopic intramembranous ossification. The lateral
and ceratobranchial, a replacement cartilage (rc), is unaffected in AP-treated
gesting transformation to persistent cartilage (*). (F) Runx2 misexpression
ement cartilage (*). Abbreviations: pc indicates persistent cartilage; rc,
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example, Sox9-treated embryos exhibited cartilage in
regions that normally contained bone (Figs. 2A, B) and
also persistent cartilages in place of replacement carti-
lages (Figs. 2D, E). In Runx2-treated embryos, persistent
cartilages were converted to replacement cartilages (Figs.
2D, F). Such changes have been noted during evolution
of the vertebrate skeleton (deBeer, 1937). We used
histological, histomorphometric, and molecular analyses
to understand better the basis for these skeletal tissue
conversions.Fig. 3. Sox9 misexpression does not affect early stages of bone formation. Coronal
L) embryos. Safranin O/fast green staining reveals osteogenic condensations in
hybridization demonstrates normal Sox9 (B), Runx2 (C), and Col2 (D) domains
detection of viral transcripts (vEnv; E). In Sox9-treated embryos, Runx2 expression
the widespread Sox9 expression (H) that results from viral infection (K). At t
magnification of the boxed regions in A and G reveals that mesenchymal condensa
Mk indicates Meckel’s cartilage; sa, surangular; SafO, Safranin O. Scale bars: 25Sox9 misexpression does not alter early stages of
osteogenesis
Regarding the potential transformation of skeletal tissue
fate from bone to cartilage as a result of Sox9 expression, we
found no differences in the early stages of bone formation in
Sox9-treated embryos. In HH30 AP-treated embryos, the
osteogenic condensation that develops into the surangular
formed in its proper location lateral to the proximal portion
of Meckel’s cartilage (Figs. 3A, F). Distinct Runx2 domains
were present outside of cartilage in regions that expressedsections through HH30 mandible of AP-treated (A–F) and Sox9-treated (G–
both AP-treated (A, F) and Sox9-treated embryos (G, L). RNA in situ
in AP-treated embryos, despite widespread viral infection, as evidenced by
(I) appears normal in regions undergoing osteogenic condensation, despite
his time point, no ectopic Col2 domains have appeared (J). (F, L) High
tion of bone (outline) is unaffected in Sox9-treated embryos. Abbreviations:
0 Am (A–E, G–L); 100 Am (F, L).
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infection, as evidenced by expression of the transcript for
the viral Envelope gene (vEnv; Fig. 3E). This high degree of
viral infection was typical of both control and experimental
embryos examined over multiple time points (data not
shown). Despite extensive infection in HH30 Sox9-treated
embryos, osteogenic condensations formed, and Runx2
domains appeared unaffected (Figs. 3G–I, K, L). Note that
at this stage, no ectopic cartilage had yet formed, as
evidenced by the lack of both ectopic Safranin O staining
and Col2 expression (Figs. 3G, J). Ectopic Col2-positive
condensations began to form, however, at HH31 in both
Runx2-positive and Runx2-negative domains of Sox9-
treated embryos, suggesting that ectopic cartilage nodules
initiated formation both inside and outside of developing
bone (data not shown). In summary, ectopic Sox9 expres-
sion did not disrupt the establishment of Runx2 domains or
osteogenic condensations.
Sox9 misexpression diverts tissue fate from bone to
replacement cartilage
Upon analysis of older Sox9-treated embryos, we found
evidence that ectopic Sox9 expression diverted the fate of
skeletal tissues from bone to replacement cartilage. Gross
examination revealed that Sox9 misexpression drastically
reduced the amount of bone that formed (34/43; Figs. 4A, B,
see also Figs. 2A, B). Histomorphometric analyses con-
firmed that Sox9-treated embryos had 10% of the bone
matrix seen in AP-treated controls (*P b 0.007; Fig. 4C).
We found, both inside and outside of bone, ectopic
chondrocytes that expressed Sox9 and Col2 and were
surrounded by Safranin O-stained matrix (compare Figs.
4D, E to H, I; data not shown). Similar to our analyses at
earlier time points, Runx2 domains were unaffected
(compare Fig. 4F to J). The ultimate fate of ectopic
chondrocytes differed, however, depending upon their
location. Molecular and histological analyses indicated that,
when the ectopic chondrocytes were found within a
developing bone, they expressed Runx2, Col10, Indian
hedgehog (Ihh), and Bone morphogenetic protein 6, and the
cells underwent hypertrophy (Figs. 4H, J, K; data not
shown). Conversely, ectopic chondrocytes located outside a
developing bone neither expressed these markers of
chondrocyte maturation nor underwent hypertrophy (Figs.
4H, J, K, white arrowheads; data not shown). Thus, Sox9
misexpression induced both ectopic persistent and replace-
ment cartilages in adjacent populations of mesenchyme.
Markers of secondary cartilage
Endochondral ossification is described typically as the
replacement of cartilage by bone; there are normal instances,
however, when bone precursor cells actually give rise to
cartilage. The process of secondary cartilage formation
occurs at articular surfaces of bones and appears to be aresponse of osteogenic cells in the periosteum to mechanical
stimuli (Buxton et al., 2003; Hall, 1986). The genetic factors
that translate this epigenetic influence into cell fate
decisions are unknown. Cells forming secondary cartilage
expressed Sox9, Runx2, Col2, Col10, and Ihh, and they also
showed signs of hypertrophy (Figs. 5A–F, data not shown).
Despite demonstrating the same histological and molecular
markers, secondary cartilage in uninfected control embryos
and the ectopic replacement cartilage in Sox9-treated
embryos represented distinct phenomena. They differed in
both the timing and precise location of their formation.
Secondary cartilage began to form in control embryos at
HH37, while ectopic cartilage in Sox9-treated embryos
began to be visualized at HH31 (data not shown). Also,
secondary cartilage was located only in close association
with the periosteum at discrete regions of the bone element,
whereas ectopic cartilage developed throughout the bones of
Sox9-treated embryos (compare Fig. 4H to Fig. 5A).
Sox9 overexpression transforms fate from replacement
cartilage to persistent cartilage
Sox family members appear to inhibitRunx2 expression in
chondrocytes, although this has never been directly addressed
experimentally (Akiyama et al., 2002; Smits et al., 2001;
Zhao et al., 1997).We found the same epistatic relationship in
cells developing into replacement cartilage, where Sox9
overexpression caused Runx2 down-regulation. The cerato-
branchial, a replacement cartilage in the second pharyngeal
arch, normally expresses Sox9, Col2, Runx2, and Col10 and
undergoes hypertrophy; this process was unaffected in AP-
treated control embryos (Figs. 6A–F, data not shown; see also
Fig. 2D). The ceratobranchial of Sox9-treated embryos
contained both Sox9 and Col2 transcripts, but did not express
Runx2 and Col10 and failed to undergo hypertrophy (Figs.
6G–L; see also Fig. 2E). This effect was not transient, as
examination of HH45 embryos revealed similar defects
(Fig. 4B, data not shown). In summary, overexpression of
Sox9 was sufficient to inhibit markers of replacement
cartilage, converting the tissue to persistent cartilage.
We also noted a lack of perichondral bone in Sox9-
treated embryos (compare Fig. 6F to L; see also Figs. 2E
and 4B). Sox9 may have repressed directly the differ-
entiation of perichondrial cells into osteoblasts (see Figs.
4A–C). On the other hand, Sox9 may have acted indirectly
by inhibiting the expression of osteogenic growth factors
that are normally produced by replacement cartilage (St-
Jacques et al., 1999; Ueta et al., 2001).
Ectopic Runx2 expression converted persistent cartilage to
replacement cartilage
The epibranchial, a persistent cartilage in the second
pharyngeal arch, normally expresses Sox9 and Col2, but not
Runx2 or Col10, and does not undergo hypertrophy; this
process was unaffected in AP-treated control embryos (Figs.
Fig. 4. Experimental conversion of tissue fate from bone to cartilage. Compared to control, uninfected heads (A), Alizarin red/Alcian blue-stained HH45 Sox9-
treated heads (B) demonstrate decreased bone and increased cartilage. (C) Histomorphometric quantification (see Materials and methods) reveals that bone
matrix in HH35 Sox9-treated embryos decreases significantly to 10% amount in AP-treated embryos (*P b 0.007). Increases in cartilage matrix were not
statistically significant, likely due to large variation in amounts of ectopic cartilage in Sox9-treated embryos. Coronal sections through HH35 mandibles of AP-
treated (D–G) and Sox9-treated (H–K) embryos show two types of ectopic cartilage as a result of Sox9 misexpression. (D, H) Safranin O staining reveals
ectopic cartilage both within and outside of bone (note periosteum, po) of Sox9-treated embryos. Only ectopic chondrocytes within bone (black arrowheads)
undergo cellular hypertrophy. White arrowheads in H–K denote the same ectopic cartilage nodule outside bone in adjacent tissue sections. RNA in situ
hybridization demonstrates Col2 transcripts in all chondrocytes (E, I). Runx2 expression remains unaffected in developing bone (F, J). Col10 expression is
detected only in the ectopic chondrocytes that are within bone (G, K). Abbreviations: Mk indicates Meckel’s cartilage; po, periosteum; sa, surangular. Scale
bars: 0.4 cm (A, B); 100 Am (D–K).
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embryos, however, expressed all of these markers and
underwent hypertrophy (Figs. 7G–L). The finding that
Runx2 is sufficient to convert a persistent cartilage to
replacement cartilage is consistent with mouse transgenic
studies (Ueta et al., 2001).
We also noted ectopic perichondral bone in Runx2-
treated embryos (compare Figs. 7A, F to G, L; also compare
Fig. 2D to F). Runx2 may have induced directly perichon-
drial cells to differentiate into osteoblasts (Ducy et al.,
1997). Alternatively, Runx2 may have acted indirectly by
inducing osteogenic growth factors in the ectopic replace-ment cartilage (St-Jacques et al., 1999; Ueta et al., 2001). In
contrast to the ectopic cartilage located within bone of
Sox9-treated embryos (see Fig. 4H), we never observed
ectopic bone within cartilage of Runx2-treated embryos.Discussion
Binary molecular code for skeletal tissue specification
Our developmental expression data and experimentally
induced skeletal tissue transformations paint a new picture
Fig. 5. Normal conversion of tissue fate from bone to cartilage. Coronal sections through a control, uninfected HH38 mandible show replacement cartilage
markers in secondary cartilage, a tissue that results when bone precursor cells give rise to cartilage (Hall, 1986). (A) Safranin O staining demonstrates cartilage
forming within bone at the surangular-Meckel’s articulation (note periosteum, po). RNA in situ hybridization reveals that secondary cartilage expresses
transcripts for Sox9 (B), Runx2 (C), Col10 (D), and Ihh (E). (F) A magnified view of the box in A demonstrates that chondrocytes in secondary cartilage begin
to undergo hypertrophy (arrow), compared to nonhypertrophic chondrocytes of Meckel’s cartilage (arrowhead). Abbreviations: Mk indicates Meckel’s
cartilage; po, periosteum; sa, surangular. Scale bars: 200 Am (A–E); 100 Am (F).
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expression patterns specifies three distinct skeletal cell
fates. In our model, an undifferentiated mesenchymal cell
can follow three skeletal fates in response to modulationsFig. 6. Transformation of replacement cartilage to persistent cartilage. Coronal sec
(G–L) embryos. Safranin O staining shows hypertrophic chondrocytes (*) and peri
absent in Sox9-treated embryos (G, L). RNA in situ hybridization demonstrates S
Sox9-treated (H, I) embryos. Note lack of Runx2 (J) and Col10 (K) expression in
magnification of the boxed regions in A and G. Scale bars: 250 Am (A–E, G–K)in Sox9 and Runx2 expression levels (Fig. 8). Two of these
fates are imparted in a manner consistent with the
traditional concept of a master regulatory gene, whereby
one transcription factor takes over the fate of a cell bytions through HH35 ceratobranchials of AP-treated (A–F) and Sox9-treated
chondral bone (arrow) in AP-treated controls (A, F), while these features are
ox9 and Col2 transcripts in ceratobranchials of both AP-treated (B, C) and
Sox9-treated embryos, compared to AP-treated controls (D, E). (F, L) High
; 100 Am (F, L).
Fig. 7. Transformation of persistent cartilage to replacement cartilage. Coronal sections through HH35 epibranchials of AP-treated (A–F) and Runx2-treated
(G–L) embryos. HBQ staining reveals ectopic hypertrophic chondrocytes (*) and ectopic perichondral bone (arrow) in Runx2-treated embryos (G, L),
compared to AP-treated controls (A, F). RNA in situ hybridization demonstrates Sox9 and Col2 transcripts in epibranchials of both AP-treated (B, C) and
Runx2-treated (H, I) embryos. Note ectopic Runx2 (J) and Col10 (K) transcripts in Runx2-treated embryos, compared to AP-treated embryos (D, E). (F, L)
High magnification of the boxed regions in A and G. Scale bars: 100 Am (A–L).
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Sox9 induces a persistent chondroblast in the presence of
low levels of Runx2, while Runx2 promotes osteoblast
differentiation if Sox9 levels are low. However, an
intermediate phenotype also exists, for the actions of both
Sox9 and Runx2 result in chondroblasts of replacement
cartilage. How can two master regulatory genes combine
to produce a third, distinct cell fate? In this paper, we
provide insight into this question by analyzing normal
skeletal development and experimentally manipulating it
through Sox9 and Runx2 misexpression.
The overlapping and nonoverlapping aspects of the
molecular controls that drive skeletal tissue formation are
obvious as cranial mesenchymal cells initiate overt histo-
genesis. Our finding that Sox9 and Runx2 are coexpressed
in cranial mesenchymal condensations of replacement
cartilage is in line with other analyses of endochondral
bone formation in the axial and appendicular skeletons
(Lengner et al., 2002; B.F. Eames, unpublished observa-
tions). Furthermore, the expression patterns of Sox9 and
Runx2 are mutually exclusive in condensations that differ-
entiate directly into bone or persistent cartilage, providingclear evidence for the nonoverlapping roles these factors
play in skeletal histogenesis.
We confirmed the functional roles of Sox9 and Runx2 in
cranial skeletogenesis by viral misexpression, employing an
infection strategy that resulted in early, widespread expres-
sion of viral genes. Since some of these treated embryos
exhibited aberrant skeletal morphogenesis, the dramatic
effects on skeletal histogenesis that we observed might be
due in part to defects in earlier aspects of embryogenesis,
such as neural crest migration and proliferation. We
addressed this possibility by injecting unilaterally RCAS–
Sox9 into postmigratory neural crest mesenchyme in HH17
pharyngeal arches and similarly observed ectopic cartilage
and decreased bone (data not shown). Also, avian neural
crest cells normally express Sox9 during and after migration
(data not shown), so our infection protocol may have
affected minimally these early stages. Only those neural
crest cells that normally initiate chondrogenesis maintain
high levels of Sox9 transcripts after HH26, whereas the rest
of the neural crest cells down-regulate Sox9 expression (data
not shown). The fact that we did not observe ectopic
cartilage nodules until HH31 may reflect the timing by
Fig. 8. Model for skeletal cell fate decisions.
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genic potential via viral Sox9 expression, although greater
understanding of cofactors for Sox9 in chondrogenesis is
required to test this hypothesis. Interestingly, ectopic
chondrocytes formed only as overt osteogenesis initiated,
suggesting that chondrogenic cofactors may have been
usurped from the osteogenic program. In general, Sox9
appears to be a potent initiator of chondrogenesis. The 5%
of Sox9-treated embryos in which we did not observe
ectopic cartilage could have resulted from human error in
either the injection protocol or histological analyses.
In comparison with other systems in which the factors
controlling cell fate specification are known, the regulation
of skeletal histogenesis by Sox9 and Runx2 has a distinct
advantage. During hematopoiesis (Cantor and Orkin, 2001)
and flower development (Coen and Meyerowitz, 1991), for
example, the number of molecular determinants equals or
exceeds the number of cell fates. Our data support a model
whereby the actions of two transcription factors combine tospecify three skeletal cell fates (Fig. 8). Due to the relatively
small number of molecular determinants, we speculate that
it will be easier to dissect the molecular mechanisms
underlying skeletal cell specification.
Conversion of skeletal tissue fates
The transformations of skeletal tissue in both Sox9- and
Runx2-treated embryos emphasize functionally the over-
lapping roles these transcription factors play in skeleto-
genesis. Most strikingly, our results demonstrate cartilage in
the place of bone as a result of Sox9 misexpression. While
our approach does not reveal unequivocally a change in cell
fate from preosteoblast to chondroblast, which would
require precise fate mapping and single cell injections, we
argue for such a conversion based on a variety of
histomorphometric, histological, and molecular analyses.
Despite widespread Sox9 misexpression, the early stages of
bone formation, such as establishment of a Runx2 domain
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At a later stage, however, ectopic cartilage was found within
developing bone, as would be expected from the diversion
of cells from an osteogenic to chondrogenic fate. In place of
bone tissue were chondrocytes that underwent hypertrophy
and expressed such markers as Runx2, Col10, Bmp6, and
Ihh. Finally, direct RCAS–Sox9 injection into osteogenic
regions of HH17 craniofacial mesenchyme also substituted
bone with ectopic cartilage (data not shown).
What type of cartilage would be expected to form from
osteogenic cells? Secondary cartilage represents a normal
conversion of preosteoblasts to a cartilage fate in response to
mechanical stress (Buxton et al., 2003; Hall, 1986). Our
histological and molecular analyses indicated that the tissue
resulting from secondary chondrogenesis shared markers
with the experimentally induced cartilages in Sox9-treated
embryos. In addition, these data argue that Sox9 expression
might be sufficient for secondary cartilage formation and
implicate Sox9 in the cellular machinery that responds to
such epigenetic factors as mechanical stress.
Sox9 and Runx2 misexpression converts between per-
sistent and replacement cartilage. In line with previous
studies (Ueta et al., 2001), we find that Runx2 expression is
sufficient to convert persistent cartilage to replacement
cartilage. The exact molecular mechanism by which Runx2
directs this tissue differentiation is unknown, but the ability
of Runx proteins to regulate transcription of signaling
molecules that have been shown to play a major role in
chondrocyte hypertrophy, such as Ihh, warrants further
investigation (Inada et al., 1999; Kim et al., 1999; St-
Jacques et al., 1999). An unexpected finding was the
conversion of replacement cartilage to persistent cartilage in
Sox9-treated embryos. Sox9 is normally expressed in
replacement cartilage, so why would the fate of this tissue
be affected by viral Sox9 expression?
Our Sox9 gain-of-function experiments complement loss-
of-function studies, which suggested that a normal part of
replacement cartilage development is the down-regulation of
Sox9 (Akiyama et al., 2002; Smits et al., 2001; Zhao et al.,
1997), by showing that persistent Sox9 expression may
inhibit chondrocyte hypertrophy and further maturation. The
viral promoter that was used to drive Sox9 expression does
not contain the endogenous Sox9 regulatory elements
required for its down-regulation. In the absence of Sox9
down-regulation, our data provide the first direct evidence
that Sox9 can inhibit Runx2 expression in replacement
chondrocytes. We observed Runx2 expression in mesen-
chyme undergoing the initial stages of replacement cartilage
formation in Sox9-treated embryos (data not shown),
suggesting that maintenance, as opposed to initiation, of
Runx2 expression in replacement chondrocytes was effected
negatively by Sox9 overexpression. Such defects were not
transitory, as skeletal elements in the anatomical position of
replacement cartilages in Sox9-treated embryos demonstra-
ted persistent cartilage histology as late as HH45. Of note, we
did not observe Runx2 inhibition in osteoblasts of Sox9-treated embryos, a finding that underscores the importance of
the cellular environment in transcriptional regulation.
Skeletogenic competence of head and limb mesenchyme
The viral constructs of this study were employed
previously to study the roles of Sox9 and Runx2 in limb
skeletogenesis, so our results allow direct comparisons
between the skeletogenic competence of limb and head
mesenchyme. Sox9 is sufficient for both limb and head
chondrogenesis (Bell et al., 1997; Healy et al., 1999; Kanzler
et al., 1998). Interestingly, we show here that Runx2 is
sufficient for head osteogenesis, but its misexpression did not
produce ectopic bone in the limb (Stricker et al., 2002). The
experimental discrepancy between these Runx2 studies likely
reflects differences in osteogenic competence between head
and limb mesenchyme. Indeed, most osteogenic mesen-
chyme of the limb resides in the thin layer of cells, the
perichondrium, surrounding each replacement cartilage
(Bruder and Caplan, 1990). In head mesenchyme, bone
forms in many additional sites, such as the dermal bones, and
labeling studies suggest a larger osteogenic population
(Noden, 1982). Our description of ectopic intramembranous
ossification in Runx2-treated embryos supports this notion,
but the molecular basis for this phenomenon is unknown. The
discovery of factors that impart cells osteogenic competence,
perhaps through microarray analyses of mesenchyme derived
from cranial neural crest and lateral plate mesoderm, might
shed light on the apparently restricted ability of Runx2 to
induce ectopic bone in vivo.
Dominance of chondrogenic over osteogenic determinants
The restricted pattern of skeletal tissue conversions
suggests that rules govern the synergy between Sox9 and
Runx2 during skeletogenesis. In total, we report here five
distinct experiments that reflect a molecular hierarchy to
genes specifying skeletal cell fate. First, Sox9 drives
chondrogenesis and Runx2 promotes osteogenesis, but
Sox9 and Runx2 coexpression is associated with cartilage
formation, not bone formation. Sox9 misexpression substi-
tutes cartilage for bone,whereas simplymisexpressingRunx2
cannot transform cells from cartilage to bone fates. Also, our
comparison between secondary cartilage and ectopic cartilage
in Sox9-treated embryos suggests that ectopic Sox9 expres-
sion can override osteogenic signals to drive secondary
chondrogenesis. Finally, we demonstrate that Sox9 over-
expression can inhibit Runx2 expression and cartilage
maturation. We conclude from these studies that Sox9’s
influence on skeletal differentiation dominates that of Runx2.
The molecular balancing act of replacement chondrocyte
differentiation
Given the dominance of chondrogenic over osteogenic
determinants, the formation of replacement cartilage must
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actions. In this paper, we focus on the early stages of
replacement cartilage differentiation, including the acquis-
ition of chondrocyte hypertrophy and Col10 expression.
Since it is expressed in neither bone nor persistent cartilage,
Col10 is the only known marker specific to replacement
cartilage, suggesting that a unique combination of tran-
scription factors may drive its expression. Col10 expression
depends upon Runx function, since many cartilages lack
Col10 expression in Runx2(/) mice (Hoshi et al., 1999;
Inada et al., 1999; Kim et al., 1999). Because the only tissue
in the body that expresses Col10 is cartilage, then some
chondrogenic factor(s) must synergize with Runx2 to drive
Col10 transcription. We speculate that Sox proteins syner-
gize with Runx proteins to drive expression of early
replacement cartilage-specific genes.
As replacement chondrocytes mature, Sox transcripts
become undetectable in hypertrophic chondrocytes, which
express Col10 (Akiyama et al., 2002; Smits et al., 2001;
Zhao et al., 1997). Despite this observation, our experiments
indicate that Sox down-regulation is not necessary at this
early stage of replacement cartilage development. Despite
constitutive Sox9 expression in infected cells, we observed
Col10 expression in the ectopic replacement chondrocytes
located within bone. Therefore, Sox9 (or a downstream
target of Sox9) can drive Col10 transcription in the presence
of osteogenic factors. On the other hand, Runx2 (or a
downstream target of Runx2) can drive Col10 transcription
in the presence of chondrogenic factors, as shown by our
transformation of persistent cartilage to replacement carti-
lage in Runx2-treated embryos. Interestingly, although Sox9
can inhibit Runx2 expression in replacement chondrocytes,
both Sox9 and Runx2 proteins are required directly or
indirectly for Col10 expression. Future analyses on direct
cross-regulation between Sox9 and Runx2 or on the
convergence of Sox9 and Runx2 on promoter regions of
replacement cartilage-specific genes, such as Col10, may
reveal novel molecular mechanisms of cell fate decisions.
After hypertrophy, replacement chondrocytes undergo
terminal differentiation, in which they express a series of
dbone-specificT genes, their surrounding matrix is degraded,
and they are replaced by the vasculature and bone (reviewed
in Eames et al., 2003). In the absence of Sox9 down-
regulation, even the ectopic replacement cartilage of near-
hatching, HH45 Sox9-treated embryos did not undergo
these later steps (data not shown). Therefore, while Sox9
down-regulation is not required for replacement chondro-
cytes to achieve hypertrophy and express Col10, it is
required for the ultimate degradation and replacement of the
cartilage template during endochondral ossification.
Implications for the evolution of skeletogenesis
Finally, our data lead to a testable, predictive model by
which to elucidate evolutionary phenomena in molecular
terms. While phenotypic changes in skeletal tissues havebeen used to document chordate evolution (deBeer, 1937;
Huxley, 1858), the underlying genotypic changes are
unknown. To bridge this gap, we discuss our findings in
the context of skeletal evolution.
The vertebrae in some teleost fish have transformed
during evolution from a skeletal tissue that forms initially as
replacement cartilage to one forming directly as bone. To
explain this evolutionary phenomenon, the British embry-
ologist Sir Gavin de Beer envisaged complex alterations in
morphogenesis (deBeer, 1937). Our data suggest a simple
molecular explanation for skeletal element tissue changes
through phylogeny: altered expression patterns of Sox9 or
Runx2 may underlie such phenotypic changes. Also,
persistent cartilage, bone, and replacement cartilage
appeared in succession during chordate phylogeny (Maisey,
1988; Smith and Hall, 1990). According to evolutionary
theory and the model presented here, animals before and
after these evolutionary innovations would be predicted to
differ functionally in Sox9 and Runx2 coding and/or
regulatory regions.Acknowledgments
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